William Blair Reiterates an 'Outperform' on Dynavax (DVAX); Heplisav VRBPAC Panel Set - What to Watch For
Tweet Send to a FriendGet Alerts DVAX Hot Sheet
Price: $2.54 +0.40%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade DVAX Now!
William Blair reiterates an 'Outperform' on Dynavax Technologies (NASDAQ: DVAX) price target of $9.00.
Analyst, Y. Katherine Xu, said, "A favorable vote could lead to potential approval and launch in the United States in first quarter 2013. We continue to assign 90% probability to eventual approval and a full adult label (18-70 years as opposed to 40-70 years). We note that Dynavax submitted Heplisav’s biological license application (BLA) in April, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults aged 18 through 70."
We summarize the key issues to watch for in the VRBPAC panel review as follows: 1) Efficacy should be unequivocal; 2) Safety will be the focus of discussion, in our opinion; and 3) Discussions might also focus on the one case of Wegener’s granulomatosis that put Heplisav on clinical hold during 2008-2009.
For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.
Shares of Dynavax Technologies closed at $3.83 yesterday, with a 52 week range of $1.75-$5.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Y. Katherine Xu, said, "A favorable vote could lead to potential approval and launch in the United States in first quarter 2013. We continue to assign 90% probability to eventual approval and a full adult label (18-70 years as opposed to 40-70 years). We note that Dynavax submitted Heplisav’s biological license application (BLA) in April, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adults aged 18 through 70."
We summarize the key issues to watch for in the VRBPAC panel review as follows: 1) Efficacy should be unequivocal; 2) Safety will be the focus of discussion, in our opinion; and 3) Discussions might also focus on the one case of Wegener’s granulomatosis that put Heplisav on clinical hold during 2008-2009.
For an analyst ratings summary and ratings history on Dynavax Technologies click here. For more ratings news on Dynavax Technologies click here.
Shares of Dynavax Technologies closed at $3.83 yesterday, with a 52 week range of $1.75-$5.34.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
- Toll Bros. (TOL) Estimates/PT Raised at Compass Point
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
William Blair
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
